TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient ...

A UNSW researcher studying the history of hepatitis B treatment uncovers the prehistory of COVID-19's famous RAT and PCR tests – and an Australian ...

Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Hepatitis B protection The two main issues related to HBV vaccination are persistence over time of antibodies and whether the waning or disappearance of antibodies permits a response to viral load.

Date: November 16, 2020 Time: 7:00am PDT So far, it has been estimated that 2 billion individuals have been infected by hepatitis B virus (HBV). Among them, 250 million have developed a chro. toggle ...

Gilead snaps ups German virology biotech MYR, nabbing a European-approved hepatitis D therapy By Ben Adams Dec 10, 2020 8:55am hepatitis B infection infectious disease mergers and acquisitions ...

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase ...

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient ...